An Open‐Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design

To establish bioequivalence (BE) of a generic test formulation with respect to a reference listed drug, it is necessary to demonstrate a comparable rate and extent to which active ingredients reach the site of action. To decrease unnecessary human testing and simulate scenarios involving specific populations or challenges with recruitment or study design, industry and regulators are increasingly considering in silico virtual bioequivalence (VBE) approaches. This tutorial introduces the VBEToolbox R package: a toolbox within the Open Systems Pharmacology framework to streamline and standardize computational VBE workflows. The package integrates in vitro and in vivo data to train pharmacokinetic models through inference of inter-individual variability from clinical data and establishment of in vitro to in vivo extrapolations. A nonparametric approach is adopted to account for uncertainties from parameter non-identifiability. The trained model is then applied to determine the study size with statistical power needed to demonstrate BE virtually. The use of the VBE tool is illustrated with two case studies. The first evaluates the VBE of petrolatum and ethylene glycol dermal formulations of testosterone by integrating in vitro skin permeation tests, vehicle/skin partitioning data, testosterone solubility data, and in vivo absorption data in a mechanistic in vitro/in vivo dermal absorption model. The second assesses the VBE of two oral bupropion formulations by integrating in vitro dissolution data in a physiologically based pharmacokinetic model. These case studies highlight essential considerations for model development, training, and extrapolation toward application for VBE assessment.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2025-09-24
DOI
https://doi.org/10.1002/psp4.70115
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An Open‐Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design

Cindy H. T. Yeung, Eleftheria Tsakalozou, Pierre Chelle, Andrea N. Edginton et al.
CPT Pharmacometrics & Systems Pharmacology
Statistical Methods in Clinical Trials
article

An Open‐Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design

Cindy H. T. Yeung, Eleftheria Tsakalozou, Pierre Chelle, Andrea N. Edginton, Michael Noel Neely, Julian D. Otalvaro, Juri Solodenko, Abdullah Hamadeh, Alona Kryshchenko, Moriah Pellowe, André Dallmann, Jörg Lippert, Walter M. Yamada, Jay Bartroff
article en

Abstract

To establish bioequivalence (BE) of a generic test formulation with respect to a reference listed drug, it is necessary to demonstrate a comparable rate and extent to which active ingredients reach the site of action. To decrease unnecessary human testing and simulate scenarios involving specific populations or challenges with recruitment or study design, industry and regulators are increasingly considering in silico virtual bioequivalence (VBE) approaches. This tutorial introduces the VBEToolbox R package: a toolbox within the Open Systems Pharmacology framework to streamline and standardize computational VBE workflows. The package integrates in vitro and in vivo data to train pharmacokinetic models through inference of inter-individual variability from clinical data and establishment of in vitro to in vivo extrapolations. A nonparametric approach is adopted to account for uncertainties from parameter non-identifiability. The trained model is then applied to determine the study size with statistical power needed to demonstrate BE virtually. The use of the VBE tool is illustrated with two case studies. The first evaluates the VBE of petrolatum and ethylene glycol dermal formulations of testosterone by integrating in vitro skin permeation tests, vehicle/skin partitioning data, testosterone solubility data, and in vivo absorption data in a mechanistic in vitro/in vivo dermal absorption model. The second assesses the VBE of two oral bupropion formulations by integrating in vitro dissolution data in a physiologically based pharmacokinetic model. These case studies highlight essential considerations for model development, training, and extrapolation toward application for VBE assessment.

CPT Pharmacometrics & Systems PharmacologyVol. 14(12)
University of Southern California (US), Dalhousie University (CA), United States Food and Drug Administration (US), Center for Drug Evaluation and Research (US), Children's Hospital of Los Angeles (US), University of Waterloo (CA), California State University, Channel Islands (US), Columbia College Hollywood (US), Bayer (Germany) (DE), The University of Texas at Austin (US)
Openalex Percentile: Top 75%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.